Erratum: Peroxisome proliferator-activated receptor-α is a functional target of p63 in adult human keratinocytes (Journal of Investigative Dermatology (2009) 129 (2376-2385) DOI:10.1038/jid.2009.92);Peroxisome proliferator-activated receptor-α is a functional target of p63 in adult human keratinocytes

Journal of Investigative Dermatology

Volumn 129, Issue 10, 2009, Pages 2376-2385

  Pozzi, Silvia ^a   Boergesen, Michael ^b   Sinha, Satrajit ^c   Mandrup, Susanne ^b   Mantovani, Roberto ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN P63;

ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; EPIDERMIS; GENE SILENCING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HOMEOSTASIS; HUMAN; HUMAN CELL; KERATINOCYTE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RECIPROCAL CHROMOSOME TRANSLOCATION; RNA INTERFERENCE; WOUND HEALING;

EID: 70349095350     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2009.262     Document Type: Erratum

References (57)

1. Antonini D, Rossi B, Rong H, Minichiello A, Di Palma T, Corrado M et al. (2006) An autoregulatory loop directs the tissue-specific expression of p63through a long-range evolutionarily conserved enhancer. Mol Cell Biol 26:3308-3318
2. Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP et al. (1997) Tissue distribution and quantification of the expression of mRNAs of peroxi-some proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 46:1319-1327
3. Bamberger C, Hafner A, Schmale H, Werner S (2005) Expression of different p63 variants in healing skin wounds suggests a role of p63 in reepithelialization and muscle repair. Wound Rep and Regener 13:41-50
4. Beretta C, Chiarelli A, Testoni B, Mantovani R, Guerrini L (2005) Regulation of the cyclin-dependent kinase inhibitor p57Kip2 expression by p63. Cell Cycle 4:1625-1631
5. Bieda M, Xu X, Singer MA, Green R, Farnham PJ (2006) Unbiased location analysis of E2F1-binding sites suggests a widespread role for E2F1 in the human genome. Genome Res 16:595-605
6. Birkaya B, Ortt K, Sinha S (2007) Novel in vivo targets of DeltaNp63 in keratinocytes identified by a modified chromatin immunoprecipitation approach. BMC Mol Biol 8:43
7. Borrelli S, Testoni B, Callari M, Alotto D, Castagnoli C, Romano RA et al. (2007) Reciprocal regulation of p63 by C/EBP delta in human keratinocytes. BMC Mol Biol 8:85
8. Borrelli S, Candi E, Alotto D, Castagnoli C, Melino G, Vigano ' MA et al. (2009) p63 regulates the caspase-8-FLIP apoptotic pathway in epidermis. Cell Death Diff 16:253-263
9. Braissant O, Wahli W (1998) Differential expression of peroxisome proliferator-activated receptor-alpha, -beta, and -gamma during rat embryonic development. Endocrinology 139:2748-2754
10. Chew CH, Samian MR, Najimudin N, Tengku-Muhammad TS (2003) Molecular characterization of six alternative spliced variants and a novel promoter in human peroxisome proliferator-activated receptor alpha. Biochem Biophys Res Commun 305:235-243
11. Chew CH, Chew GS, Najimudin N, Tengku-Muhammad TS (2007) Interleukin-6 inhibits human peroxisome proliferator activated receptor alpha gene expression via CCAAT/enhancer-binding proteins in hepa-tocytes. Int J Biochem Cell Biol 39:1975-1986
12. D'Erchia AM, Tullo A, Lefkimmiatis K, Saccone C, Sbisa E (2006) The fatty acid synthase gene is a conserved p53 family target from worm to human. Cell Cycle 5:750-758
13. Gaub MP, Bellard M, Scheuer I, Chambon P, Sassone-Corsi P (1990) Activation of the ovalbumin gene by the estrogen receptor involves the fos-jun complex. Cell 63:1267-1276
14. Gervois P, Pineda-Torra I, Chinetti G, Grotzinger T, Guillaume D, Fruchart JC et al. (1999) A truncated human peroxisome proliferators-activated receptor a splice variant with dominant negative activity. Mol Endocrinol 13:1535-1549
15. Ghioni P, Bolognese F, Duijf PH, Van Bokhoven H, Mantovani R, Guerrini L (2002) Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains. Mol Cell Biol 22:8659-8668
16. Gonzalez FJ (1997) The role of peroxisome proliferator activated receptor alpha in peroxisome proliferation, physiological homeostasis, and chemical carcinogenesis. Adv Exp Med Biol 422:109-125
17. Gu X, Lundqvist EN, Coates PJ, Thurfjell N, Wettersand E, Nylander K (2006) Dysregulation of TAp63 mRNA and protein levels in psoriasis. J Invest Dermatol 126:137-141
18. Juge-Aubry C, Pernin A, Favez T, Burger AG, Wahly W, Meier CA et al. (1997) DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. J Biol Chem 272:25252-25259
19. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ et al. (1994) Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 91:7355-7359
20. Komuves LG, Hanley K, Lefebvre AM, Man MQ, Ng DC, Bikle DD et al. (2000) Stimulation of PPARalpha promotes epidermal keratinocyte differentiation in vivo. J Invest Dermatol 115:353-360
21. Koster MI, Dai D, Marinari B, Sano Y, Costanzo A, Karin M et al. (2007) p63 induces key target genes required for epidermal morphogenesis. Proc Natl Acad Sci USA 104:3255-3260
22. Kurokawa I, Mizutani H, Kusumoto K, Nishijima S, Tsujita-Kyutoku M, Shikata N et al. (2006) Cytokeratin, filaggrin, and p63 expression in reepithelialization during human cutaneous wound healing. Wound Rep Regen 14:38-45
23. Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL et al. (1995) Targeted disruption of the alpha isoform of the peroxisome proliferator- activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15:3012-3022
24. Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, Rieusset J et al. (2001) Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. J Cell Biol 154:799-814
25. Michalik L, Feige JN, Gelman L, Pedrazzini T, Keller H, Desvergne B et al. (2005) Selective expression of a dominant-negative form of peroxisome proliferator-activated receptor in keratinocytes leads to impaired epidermal healing. Mol Endocrinol 19:2335-2348
26. Michalik L, Wahli W (2007) Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease. Biochim Biophys Acta 1771:991-998
27. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A (1999) p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398:708-713
28. Mukherjee R, Jow L, Noonan D, McDonnell DP (1994) Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. J Steroid Biochem Mol Biol 51:157-166
29. Noszczyk BH, Majewski ST (2001) p63 expression during normal cutaneous wound healing in humans. Plast reconstr Surg 108:1242-1247
30. Ortt K, Sinha S (2006) Derivation of the consensus DNA-binding sequence for p63 reversal unique requirements that are distinct from p53. FEBS Lett 580:4544-4550
31. Parsa R, Yang A, McKeon F, Green H (1999) Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. J Invest Dermatol 113:1099-1105
32. Perez CA, Ott J, Mays DJ, Pietenpol JA (2007) p63 consensus DNA-binding site: identification, analysis and application into a p63MH algorithm. Oncogene 26:7363-7370
33. Pineda-Torra I, Jamshidi Y, Flavell DM, Fruchart JC, Staels B (2002) Characterization of the human PPARalpha promoter: identification of a functional nuclear receptor response element. Mol Endocrinol 16:1013-1028
34. Pozzi S, Zambelli F, Merico D, Pavesi G, Robert A, Malte 're P et al. (2009) Transcriptional network of p63 in human keratinocytes. PLoS ONE 4(3):e5008. doi: 10.1371/Journal.pone.0005008.
35. Reddy JK (2001) Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. Am J Physiol Gastro-intest Liver Physiol 281:G1333-9
36. Romano RA, Birkaya B, Sinha S (2006) Defining the regulatory elements in the proximal promoter of DeltaNp63 in keratinocytes: Potential roles for Sp1/Sp3, NF-Y, and p63. J Invest Dermatol 126:469-479
37. Schmuth M, Jiang YJ, Dubrac S, Elias PM, Feingold KR (2008) Peroxisome proliferator-activated receptors (PPAR) and liver X receptor (LXR) in epidermal biology. J Lipid Res 49:499-509
38. Semenkovich CF (1997) Regulation of fatty acid synthase (FAS). Prog Lipid Res 36:43-53
39. Senoo M, Pinto F, Crum CP, McKeon F (2007) p63 is essential for the proliferative potential of stem cells in stratified epithelia. Cell 129:523-536
40. Shen CS, Tsuda T, Fushiki S, Mizutani H, Yamanishi K (2005) The expression of p63 during epidermal remodeling in psoriasis. J Dermatol 32: 236-242
41. Shemshedini L, Knauthe R, Sassone-Corsi P, Pornon A, Gronemeyer H (1991) Cell-specific inhibitory and stimulatory effects of Fos and Jun on transcription activation by nuclear receptors. EMBO J 10:3839-3849
42. Sommer M, Poliak N, Upadhyay S, Ratovitski E, Nelkin BD, Donehower LA et al. (2006) DNp63a overexpression induces downregulation of Sirt1 and an accelerated aging phenotype in the mouse. Cell Cycle 5:2005-2011
43. Staumont-Salle D, Abboud G, Brenuchon C, Kanda A, Roumier T, Lavogiez C et al. (2008) Peroxisome proliferator-activated receptor a regulates skin inflammation and humoral response in atopic dermatitis. J Allergy Clin Immunol 121:962-968
44. Testoni B, Borrelli S, Tenedini E, Alotto D, Castagnoli C, Piccolo S et al. (2006a) Identification of new p63 targets in human keratinocytes. Cell Cycle 5:2805-2811 (Pubitemid 44901743)
45. Testoni B, Mantovani R (2006b) Mechanisms of transcriptional repression of cell-cycle G2/M promoters by p63. Nucleic Acids Res 34:928-938
46. Tien ES, Davis JW, Vanden Heuvel JP (2004) Identification of the CREB-binding/p300-interacting protein CITED2 as a peroxisome proliferator-activated receptor alpha activator. J Biol Chem 279:24053-24063
47. Ventura A, Meissner A, Dillon CP, McManus M, Sharp PA, Parijs LV et al. (2004) Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci USA 10:10380-10385
48. Vigano MA, Lamartine J, Testoni B, Merico D, Alotto D, Castagnoli C et al. (2006) New p63 targets in keratinocytes identified by a genome-wide approach. EMBO J 25:5105-5116 (Pubitemid 44658528)
49. Vigano MA, Mantovani R (2007) Hitting the numbers: the emerging network of p63 targets. Cell Cycle 6:233-239
50. Vohl MC, Lepage P, Gaudet D, Brewer CG, Betard C, Perron P et al. (2000) Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia. J Lipid Res 41:945-952
51. Westergaard M, Henningsen J, Svendsen ML, Johansen C, Jensen UB, Schroder HD et al. (2001) Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. J Invest Dermatol 116:702-712
52. Westergaard M, Henningsen J, Johansen C, Rasmussen S, Svendsen ML, Jensen UB et al. (2003) Expression and localization of peroxisome proliferator- activated receptors and nuclear factor kappaB in normal and lesional psoriatic skin. J Invest Dermatol 121:1104-1117
53. Westfall MD, Mays DJ, Sniezek JC, Pietenpol JA (2003) The DeltaNp63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol Cell Biol 23: 2264-2276
54. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V et al. (1998) p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2:305-316
55. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT et al. (1999) p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398:714-718
56. Yang Q, Yamada A, Kimura S, Peters JM, Gonzalez FJ (2006a) Alterations in skin and stratified epithelia by constitutively activated PPARalpha. J Invest Dermatol 126:374-385
57. Yang A, Zhu Z, Kapranov P, McKeon F, Church GM, Gingeras TR et al. (2006b) Relationship between p63 binding, DNA sequence, transcription activity, and biological function in human cells. Mol Cell 24:593-602